Edition:
United Kingdom

Paratek Pharmaceuticals Inc (PRTK.OQ)

PRTK.OQ on NASDAQ Stock Exchange Global Market

9.68USD
5:56pm BST
Change (% chg)

$0.03 (+0.31%)
Prev Close
$9.65
Open
$9.57
Day's High
$9.83
Day's Low
$9.40
Volume
80,811
Avg. Vol
138,692
52-wk High
$24.38
52-wk Low
$8.69

Chart for

About

Paratek Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an... (more)

Overall

Beta: 0.96
Market Cap(Mil.): $705.13
Shares Outstanding(Mil.): 27.76
Dividend: --
Yield (%): --

Financials

  PRTK.OQ Industry Sector
P/E (TTM): -- 85.92 33.73
EPS (TTM): -4.01 -- --
ROI: -64.38 0.63 14.31
ROE: -87.28 1.68 16.04

U.S. FDA panel backs approval of Paratek's antibiotic

A U.S. Food and Drug Administration expert panel on Wednesday voted in favor of approval of Paratek Pharmaceuticals Inc's antibiotic to treat bacterial pneumonia and skin infections.

08 Aug 2018

UPDATE 1-U.S. FDA panel backs approval of Paratek's antibiotic

Aug 8 A U.S. Food and Drug Administration expert panel on Wednesday voted in favor of approval of Paratek Pharmaceuticals Inc's antibiotic to treat bacterial pneumonia and skin infections.

08 Aug 2018

U.S. FDA panel backs approval of Paratek's antibiotic

Aug 8 A U.S. Food and Drug Administration expert panel on Wednesday voted in favor of approval of Paratek Pharmaceuticals Inc's antibiotic to treat bacterial pneumonia and skin infections.

08 Aug 2018

Paratek antibiotic not inferior to current treatments: FDA staff

Paratek Pharmaceuticals Inc's new antibiotic for bacterial pneumonia and skin infections is not inferior to current treatments, U.S. Food and Drug Administration staff reviewers said on Monday.

06 Aug 2018

UPDATE 1-Paratek antibiotic not inferior to current treatments-FDA staff

* Drug could bring in U.S. sales of $535 mln in 2025-analysts

06 Aug 2018

BRIEF-Paratek Pharmaceuticals Reports Q1 Loss Per Share $0.91

* PARATEK PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

09 May 2018

BRIEF-Paratek Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

* PARATEK ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4) Source text for Eikon: Further company coverage:

01 May 2018

BRIEF-Highbridge Capital Management Reports 6.54 Pct Passive Stake In Paratek Pharmaceuticals

* HIGHBRIDGE CAPITAL MANAGEMENT, LLC REPORTS 6.54 PERCENT PASSIVE STAKE IN PARATEK PHARMACEUTICALS INC AS OF APRIL 23, 2018 - SEC FILING Source : https://bit.ly/2HIcM0E Further company coverage: (Reuters.Briefs@thomsonreuters.com)

30 Apr 2018

BRIEF-Paratek Pharmaceuticals Prices $140 Mln Of Convertible Senior Subordinated Notes Due 2024

* PARATEK PHARMACEUTICALS, INC. PRICES $140 MILLION OF CONVERTIBLE SENIOR SUBORDINATED NOTES DUE 2024

19 Apr 2018

BRIEF-Paratek Pharmaceuticals Announces Proposed Private Offering Of $125 Mln Of Convertible Senior Subordinated Notes Due 2024

* PARATEK PHARMACEUTICALS, INC. ANNOUNCES PROPOSED PRIVATE OFFERING OF $125 MILLION OF CONVERTIBLE SENIOR SUBORDINATED NOTES DUE 2024

18 Apr 2018

Earnings vs. Estimates